Payment overview · 2025
General Payments
$76.48
4 reported records · 4 companies
Healthcare provider profile · identity verified
James Lee Williams, FNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · MIDDLESBORO, KY · NPI 1477184331
Verified facts
What the public records show
CMS Open Payments records show James Lee Williams, FNP received $76.48 in general payments during 2025 across 4 reported records.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 36.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Linzess by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $27.89 | 36.5% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $19.05 | 24.9% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $15.18 | 19.9% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $14.36 | 18.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $76.48 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $27.89 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $19.05 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $19.05 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $15.18 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $14.36 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 84 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
52 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
84 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 488 | 90 |
| Gabapentin | Gabapentin | 384 | 69 |
| Omeprazole | Omeprazole | 294 | 66 |
| Levothyroxine Sodium | Levothyroxine Sodium | 257 | 46 |
| Atorvastatin Calcium | Atorvastatin Calcium | 233 | 50 |
| Lisinopril | Lisinopril | 212 | 58 |
| Metoprolol Tartrate | Metoprolol Tartrate | 186 | 36 |
| Metformin Hcl | Metformin Hcl | 179 | 36 |
| Pantoprazole Sodium | Pantoprazole Sodium | 171 | 38 |
| Ibuprofen | Ibuprofen | 170 | 43 |
| Methylprednisolone | Methylprednisolone | 155 | 108 |
| Amlodipine Besylate | Amlodipine Besylate | 148 | 33 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 143 | 49 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 137 | 37 |
| Hydrochlorothiazide | Hydrochlorothiazide | 134 | 29 |
| Montelukast Sodium | Montelukast Sodium | 134 | 26 |
| Ventolin Hfa | Albuterol Sulfate | 126 | 29 |
| Atenolol | Atenolol | 122 | 23 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 117 | 31 |
| Ondansetron Odt | Ondansetron | 116 | 41 |
| Simvastatin | Simvastatin | 113 | 27 |
| Azithromycin | Azithromycin | 99 | 79 |
| Potassium Chloride | Potassium Chloride | 99 | 27 |
| Fluticasone Propionate | Fluticasone Propionate | 90 | 20 |
| Furosemide | Furosemide | 87 | 26 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 85 | 19 |
| Ozempic | Semaglutide | 84 | 15 |
| Meloxicam | Meloxicam | 83 | 20 |
| Promethazine Hcl | Promethazine Hcl | 80 | 30 |
| Alprazolam | Alprazolam | 79 | 15 |
| Diazepam | Diazepam | 79 | 19 |
| Clonidine Hcl | Clonidine Hcl | 76 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 73 | 27 |
| Celecoxib | Celecoxib | 72 | 20 |
| Clindamycin Hcl | Clindamycin Hcl | 70 | 42 |
| Fenofibrate | Fenofibrate Nanocrystallized | 69 | 18 |
| Baclofen | Baclofen | 68 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 66 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 66 | 11 |
| Losartan Potassium | Losartan Potassium | 65 | 18 |
| Prednisone | Prednisone | 65 | 34 |
| Trazodone Hcl | Trazodone Hcl | 65 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 64 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 64 | 12 |
| Methocarbamol | Methocarbamol | 61 | 16 |
| Tamsulosin Hcl | Tamsulosin Hcl | 61 | 16 |
| Buspirone Hcl | Buspirone Hcl | 60 | 13 |
| Famotidine | Famotidine | 59 | 13 |
| Clonazepam | Clonazepam | 57 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 55 | 19 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 53 | 12 |
| Linzess | Linaclotide | 52 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 51 | 14 |
| Amoxicillin | Amoxicillin | 48 | 34 |
| Mounjaro | Tirzepatide | 47 | suppressed |
| Bumetanide | Bumetanide | 46 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 46 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 45 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 45 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 43 | suppressed |
| Nitroglycerin | Nitroglycerin | 43 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 42 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 42 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 41 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 41 | suppressed |
| Eliquis | Apixaban | 40 | suppressed |
| Gemfibrozil | Gemfibrozil | 40 | suppressed |
| Topiramate | Topiramate | 40 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 39 | suppressed |
| Fluconazole | Fluconazole | 37 | 22 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 37 | 11 |
| Ofloxacin | Ofloxacin | 37 | 23 |
| Valsartan | Valsartan | 36 | suppressed |
| Cefdinir | Cefdinir | 35 | 24 |
| Pregabalin | Pregabalin | 35 | 11 |
| Levofloxacin | Levofloxacin | 34 | 23 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 34 | suppressed |
| Allopurinol | Allopurinol | 33 | suppressed |
| Spironolactone | Spironolactone | 33 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 32 | suppressed |
| Carvedilol | Carvedilol | 31 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 30 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 30 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 30 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 30 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 29 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 28 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 28 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 27 | 21 |
| Dicyclomine Hcl | Dicyclomine Hcl | 27 | suppressed |
| Fenofibrate | Fenofibrate | 27 | suppressed |
| Glipizide | Glipizide | 27 | suppressed |
| Jardiance | Empagliflozin | 27 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 26 | 18 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 24 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 24 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 23 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 23 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 23 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 23 | 14 |
| Brilinta | Ticagrelor | 22 | suppressed |
| Januvia | Sitagliptin Phosphate | 22 | suppressed |
| Nystatin | Nystatin | 22 | 11 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 22 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 22 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 21 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 21 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 20 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 20 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 19 | suppressed |
| Ezetimibe | Ezetimibe | 19 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 19 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 19 | suppressed |
| Vascepa | Icosapent Ethyl | 18 | suppressed |
| Lactulose | Lactulose | 16 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 16 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 15 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 15 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 15 | 13 |
| Metformin Hcl Er | Metformin Hcl | 15 | suppressed |
| Nicotrol Ns | Nicotine | 15 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 15 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 15 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 14 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 14 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 14 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 14 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 13 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Risperidone | Risperidone | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | suppressed |
| Methotrexate | Methotrexate Sodium | 12 | suppressed |
| Mirtazapine | Mirtazapine | 12 | suppressed |
| Pen Needles | Pen Needle, Diabetic | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 11 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 11 | suppressed |
| Xarelto | Rivaroxaban | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $76.48 · 4 records | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA, INGREZZA, Ozempic, Rybelsus, VRAYLAR | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error